All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.

The Lupus Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lupus Hub cannot guarantee the accuracy of translated content. The Lupus Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Lupus Hub

Brought to you by Scientific Education Support

Scientific Education Support

The Lupus Hub is an independent medical education platform, sponsored by Autolus, Biogen and Biogen MA, Inc. and UCB. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

My Lupus Hub

Create an account to access:

Bookmark & personalize site content

Receive alerts for new content in your areas of interest

View lupus content recommended for you

EULAR 2023

Share:

Jun 1, 2023

X post image

7 Jun 2023

Our #EULAR2023 coverage has now finished. Thank you for following, we hope you found our coverage useful!
#Lupus #SLE
@eular_org

X post image

5 Jun 2023

CONGRESS #EULAR2023 | @edvital presented a late-breaking abstract on the #SLE ROOTS trial that used objective eligibility criteria to evaluate rituximab. At week 4 and 8, placebo pts performed better in efficacy evaluations, but at later endpoints rituximab efficacy improved.

X post image

5 Jun 2023

CONGRESS #EULAR2023 | Coziana Ciurtin presented a late-breaking abstract on biomarker stratification in the APPLE trial, of pediatric pts with #SLE. Pts in placebo arm had 2 distinct patterns of CIMT progression, atorvastatin treated pts had 3 patterns of CIMT progression.

X post image

2 Jun 2023

CONGRESS #EULAR2023 | @george_bertsias discussed #SLE risk prediction. 22.1% pts developed classifiable SLE by ACR/EULAR criteria. Family history & smoking were predictive for dev from 'at risk' to classifiable SLE. Type 1 IFN pathway was found to be involved in SLE dev. #lupus

X post image

2 Jun 2023

CONGRESS #EULAR2023 | @sarahdyball1 presented results from the BILAG-BR study of 1601 pts with #SLE. White pts were least likely to have renal involvement, 56% of all pts achieved clinical response at 12 mo, and black or south Asian patients were less likely to respond. #lupus

X post image

2 Jun 2023

CONGRESS #EULAR2023 | @LouKawka discussed the digital LEAF tool to assess fatigue in pts with #lupus. 1250 pts were included in the study, and 78.9% had significant fatigue. Fibromyalgia, clinical insomnia, and high stress levels were all associated with significant fatigue.

X post image

2 Jun 2023

CONGRESS #EULAR2023 | Iñigo Rua-Figueroa discussed retrospective data from the RELESSER registry of causes of lupus mortality, from the 1980s to 2000s. Death rate decreased over the time periods, and causes of death over time has changed.

X post image

2 Jun 2023

CONGRESS #EULAR2023 | Dong-Jin Park presented results from the KORNET study of kidney disease in LN. 175 pts were enrolled. In pts with tubulointerstitial inflammation, CKD (45.5%) and death (4.5%) was more common compared to pts without TII (18.5% and 0%). #lupus

X post image

2 Jun 2023

CONGRESS #EULAR2023 | Xingbei Dong spoke on the results from a 10 year study of patients with #SLE and pulmonary arterial hypertension (PAH). The main cause of death in SLE-PAH pts was PAH exacerbation (57%). 20% of high-risk pts died within one year of diagnosis. #lupus

X post image

2 Jun 2023

CONGRESS #EULAR2023 | @andreafava presented data on urinary biomarker levels at 3 months predicting treatment response at 12 months. CD206, CD163 and IL16 better predict treatment response in proliferative LN than proteinuria.
#Lupus #lupusnephritis

X post image

2 Jun 2023

CONGRESS #EULAR2023 | @EricFMorand, @MonashUni discussed how achievement of LLDAS with and without remission (REM) prevents adverse #SLE outcomes. 18% of pts achieved LLDAS without REM. Attainment of LLDAS even without REM significantly protected against flare and damage accrual.

X post image

2 Jun 2023

#EULAR2023 https://t.co/ZPHhwRueLS

X post image

1 Jun 2023

CONGRESS #EULAR2023 | Georg Schett @UniFAU updated us on the use of CD19 CAR-T cells in patients with refractory #SLE. #Lupus resolved rapidly after infusion, with an increase in complement C3 after 3 months. All patients achieved SLEDAI remission during follow up.

X post image

1 Jun 2023

CONGRESS #EULAR2023 | Joan T Merrill presented phase II SLEek study data of ABBV-599 (elsubrutinib and upadacitinib) vs upadacitinib monotherapy for #SLE. The primary endpoint of SRI-4 response was met at Week 48 in both groups (51.5% for ABBV-599 & 45.2% for monotherapy). #lupus

X post image

1 Jun 2023

CONGRESS #EULAR2023 | Ronald van Vollenhoven, @amsterdamumc, presented phase III data from study of novel BLyS/APRIL inhibitor telitacicept vs pbo in 335 pts with #SLE. 67.1% of telitacicept pts achieved SRI-4 at Week 52. There were less SAEs in telitacicept group vs pbo. #lupus

X post image

31 May 2023

CONGRESS #EULAR2023 | Dr Jay Rothstein presented early stage data for INX200, an anti-VISTA targeted GC antibody conjugate. INX200 may offer non-toxic GC treatment of autoimmune diseases, including #SLE, reducing GC exposure to non-immune tissues, with an SC formulation. #lupus

X post image

31 May 2023

CONGRESS #EULAR2023 | Yasuhiro Katsumata presented data on organ damage after GC tapering in patients with serologically active, clinically quiescent #SLE, finding that tapering GC reduced risk of damage accrual in these patients treated with more than 5mg pd GC. #lupus

X post image

31 May 2023

CONGRESS #EULAR2023 | @AishwaryaGopal @JIPMER discussed the withdrawal of maintenance GCs vs other IS in patients with #SLE. GC withdrawal was found to be non-inferior to IS withdrawal mat 52 weeks. #lupus

X post image

31 May 2023

CONGRESS #EULAR2023 | @Lupusreference presented results of the LUPIN-F study on doses of oral corticosteroids (OCS) in #SLE for population-based nationwide French study of 31852 patients, highlighting that 27.4% of patients were receiving only OCS. #lupus

X post image

31 May 2023

We are happy to be covering #EULAR2023. A busy opening plenary to start the congress.
#lupus

<span> </span>

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content

More about...

EULAR 2023 European Alliance of Associations for Rheumatology

Newsletter

Subscribe to get the best content delivered to your inbox